Search
Temafloxacin
go.drugbank.com/drugs/DB01405ApprovedWithdrawnIt was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three … Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class.
Pimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. … It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema).
Metiamide
go.drugbank.com/drugs/DB08805ExperimentalMetiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Panitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalThis drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]
Oxprenolol
go.drugbank.com/drugs/DB01580ApprovedWithdrawnA beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Fexapotide
go.drugbank.com/drugs/DB05493InvestigationalNX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed.
Categories: Drugs Used in Benign Prostatic HypertrophyOmidubicel
go.drugbank.com/drugs/DB17132ApprovedInvestigationalIn addition, the fact that 39% of the study's cohort were non-White patients highlights the importance of this type of treatment in key demographics with low donor availability. … Umbilical blood cord cells are expanded _ex-vivo_ and [nicotinamide] (a form of vitamin B3) is used as an active agent in the culture system to inhibit the differentiation and increase the functionality
Synonyms: Allogeneic, ex-vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells - cultured fraction (CF)Selexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalcirculation and decrease elevated pressure in the blood vessels supplying blood to the lungs. … Selexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization.
Synthetic Conjugated Estrogens, A
go.drugbank.com/drugs/DB09317ApprovedPharmacologic estrogen products are available in a variety of formats. … However, once a woman stops ovulating there is a sharp decline in the production of progesterone and estradiol by the ovaries and a consequent fluctuation in LH and FSH due to a lack of feedback control
Copanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalPI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies. … [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]
Synonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE